Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Inc.
Age
12–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are participating in either Study 207, Study 307, or Study 235 and who in the opinion of the treating physician, continue to benefit from treatment with perampanel (revised per Amendment 01)
Patients who provide informed consent where applicable per local requirements.
Female patients of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (e.g., a double-barrier method \[condom plus spermicide, condom plus diaphragm with spermicide\])
You may not be if
Patients residing in countries where perampanel is commercially available for the treatment of POS
Female patients who are lactating, pregnant, or planning to become pregnant
Clareo Health | An Extended Access Program for Perampanel
